23 Jul, 2026
According to Straits Research, the global liquid handling system market valued at $5.7 billion in 2025, is projected to grow from $6.17 billion in 2026 to $11.61 billion by 2034 at a CAGR of 8.23% during the forecast period 2026–2034.
Liquid handling systems are a collection of apparatuses for administering, manipulating, and storing liquid samples. The automated liquid handling system includes electronic pipetting systems, microplate cleansers, and dispensers for liquid sampling; it employs robotics and automation to expedite large-scale production and reduce turnaround time. ELISA, cell culture, RNA/DNA purification, PCR/Sequencing reaction setup, reaction cleansing, protein purification, automated detection assays, and MALDI-TOF spotting are performed with these systems. These systems reduce the likelihood of contamination, labor expenses, and inconsistencies in sample yield and produce uniform quantities.
Increased liquid handling system automation is anticipated to increase efficiency, reduce cleaning expenses, eliminate costly safety and ergonomic issues, and lower ingredient costs. Manufacturers are attempting to find cost-effective ways to satisfy the growing demand in the biopharmaceutical industry amidst rising labor costs. In addition to technological advancements, consumers expect businesses to prioritize cost reductions rather than passing on price increases. Cost reduction for manufacturers necessitates optimizing plant efficiency through increased automation. These expenditures in automation have increased output per person-hour and decreased unit costs. Automated systems can reduce expenses by increasing productivity, resolving price, safety, and hygiene issues, adding flexibility to production lines, and eliminating product contamination and other problems.
Recent growth in biopharmaceutical sales has been attributed to several factors, including the elderly baby boomer population, the rising prevalence of chronic illnesses, and a greater emphasis on targeted therapy. The increasing global demand for biopharmaceuticals has stimulated global production. With increased research and clinical trials conducted by biopharmaceutical manufacturers, the biopharmaceutical production industry has experienced a rise in productivity. In addition, the outbreak of the COVID-19 pandemic has increased the focus of biopharmaceutical companies on the growth of effective antiviral medications and vaccines for SARS-CoV infection. In this context, establishing efficient workflows with automation and robotics to reduce the time and costs associated with drug and vaccine development has become increasingly important. This creates opportunities for the market expansion of liquid handling systems.
North America dominated the market share and is estimated to grow at a CAGR of 6.7% during the forecast period. The United States leads the world in terms of research and development spending in life sciences, pharmaceuticals, and analytical chemistry. It is among the largest markets for bulk drugs and finished dosage formulations, for which liquid handling systems are used for drug production. As liquid handling systems are used extensively in drug discovery, cancer research, and clinical diagnostics, these industries' growth is expected to impact the market positively. Other factors, such as an increase in infectious and chronic diseases, investments by major companies, and a higher number of products launched by market players, are expected to boost market growth.
Europe is the second largest region. It is estimated to reach an expected value of USD 2160 million by 2031, registering a CAGR of 6.5%. The German healthcare system provides patients with access to technologically advanced products, and it is a high-focus market for most diagnostic manufacturers. High government investment, a rise in the prevalence of chronic and infectious diseases, and growing product launches are some of the growth factors driving the market. Cardiovascular diseases, infectious diseases, such as COVID-19, diabetes, and kidney-related complications pose huge burdens on the country. According to an article published in 2018 in PLoS One titled, "Who is Where at Risk for Chronic Obstructive Pulmonary Disease? A Spatial Epidemiological Analysis of Health Insurance Claims for COPD in Northeastern Germany", the prevalence of chronic obstructive pulmonary disease (COPD) ranges from 1.3% to 13.2%, which may grow by 24% by 2030. As per the Johns Hopkins University, around 3,692,908 confirmed cases of COVID-19 were reported in Germany, with around 88,781 deaths, as of June 1st, 2021. This led to a massive increase in research, increasing the demand for liquid handling systems.
sales@straitsresearch.com